Search

Your search keyword '"Kyrgidis, Athanassios"' showing total 467 results
Start Over Author "Kyrgidis, Athanassios" Publication Year Range Last 50 years
467 results on '"Kyrgidis, Athanassios"'

9. CONGENITAL CYSTIC NECK LESIONS: A SINGLE-CENTRE STUDY

Author

Chrysostomidis, Anestis, primary, Louizakis, Alexandros, additional, Michailidou, Despoina, additional, Grivas, Theodoros, additional, Pasteli, Nikoleta, additional, Kyrgidis, Athanassios, additional, Boukovinas, Ioannis, additional, and Vahtsevanos, Konstantinos, additional

Published
2024
Full Text
View/download PDF

13. Minimal Clinically Important Differences in the Cancer Quality of Life Questionnaires in Patients with Head and Neck Cancer.

Author

Kyrgidis, Athanassios, Printza, Athanasia, Vitkos, Evangelos, Lallas, Konstantinos, Vlassi, Alexandra, Constantinidis, Jannis, and Triaridis, Stefanos

Subjects
*HEAD & neck cancer, *KARNOFSKY Performance Status, *PHYSICAL mobility, *CANCER patients, *QUALITY of life
Abstract

Purpose: The purpose of this study is to determine the magnitude of change that is clinically meaningful in the EORTC QLQ-C30 and EORTC QLQ-HN35 instruments in head and neck cancer patients. Methods: Two hundred and twenty-two patients completed the EORTC QLQ-C30 and EORTC QLQ-HN35 at baseline and follow-up one to two months later. Minimal clinically important differences (MCIDs) were calculated through anchor- and distribution-based methods for improvement and deterioration. Karnofsky Performance status (KPS) was used as the anchor to determine meaningful change. Results: In the group of patients who deteriorated, more scales and symptoms demonstrated statistically significant meaningful change. EORTC QLQ-C30 meaningful change values for deterioration with KPS anchor ranged from 7.2 (physical functioning) to 16.7 units (Global Health Status), and for improvement ranged from 10.0 (role functioning) to 16.7 units (Global Health Status). Conclusions: We report—for the first time, to the best of our knowledge—MCID for EORTC QLQ-C30 and QLQ-HN35 in head and neck cancer patients. Knowledge of meaningful change in these questionnaires allows physicians to assess patient change over time, along with evaluating the impact of treatment on quality of life. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Dermatoscopic predictors of histopathologically aggressive basal cell carcinoma and their positive impact of subtype prediction by human readers.

Author

Camela, Elisa, Ilut Anca, Paula, Kyrgidis, Athanassios, Lallas, Konstantinos, Scalvenzi, Massimiliano, Papageorgiou, Chryssoula, Manoli, Sofia-Magdalini, Gkentsidi, Theodosia, Eftychidou, Polychronia, Delli, Florentina Silvia, Eleftheriadis, Vlassios, Sakellaropoulou, Stella, Papadimitriou, Ilias, Badiu, Iulia Maria, Cutoiu, Ana, Korecka, Katarzyna, Vakirlis, Efstratios, Sotiriou, Elena, Apalla, Zoe, and Lallas, Aimilios

Published
2024
Full Text
View/download PDF

15. Dermatoscopy of nodular/plaque-type primary cutaneous T- and B-cell lymphomas: A retrospective comparative study with pseudolymphomas and tumoral/inflammatory mimickers by the International Dermoscopy Society

Author

Errichetti, Enzo, Geller, Shamir, Zalaudek, Iris, Longo, Caterina, Kyrgidis, Athanassios, Akay, Bengu Nisa, Piccolo, Vincenzo, Myskowski, Patricia, Vitiello, Paola, Russo, Teresa, Argenziano, Giuseppe, Sławińska, Martyna, Sokołowska-Wojdyło, Małgorzata, Sobjanek, Michał, Toncic, Ruzica Jurakic, Rados, Jaka, Drvar, Daniela Ledic, Ceovic, Romana, Kaminska-Winciorek, Grażyna, Zaballos, Pedro, Reggiani, Camilla, Kremic, Zorana, Lanssens, Sven, Güleç, Ayşe Tülin, Lobato-Berezo, Alejandro, Damiani, Giovanni, Maione, Vincenzo, Calzavara-Pinton, Piergiacomo, Sotiriou, Elena, Stinco, Giuseppe, Apalla, Zoe, and Lallas, Aimilios

Published
2022
Full Text
View/download PDF

17. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.

Author

Zouboulis, Christos C., Kyrgidis, Athanassios, Alavi, Afsaneh, Jemec, Gregor B. E., Martorell, Antonio, Marzano, Angelo V., van der Zee, Hessel H., Wozniak, Magdalena B., Martinez, Angela Llobet, Kasparek, Torben, Bachhuber, Teresa, Ortmann, Christine‐Elke, Lobach, Iryna, Thomas, Nicolas, Ravichandran, Shoba, and Tzellos, Thrasyvoulos

Subjects
*ADULTS, *CLINICAL trials, *SUNSHINE, *PLACEBOS, *TUNNELS
Abstract

Introduction Objective Methods Results Conclusions The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool that measures inflammatory lesions, including draining tunnels, in hidradenitis suppurativa (HS).To evaluate secukinumab efficacy using IHS4 in patients with moderate to severe HS.Data from the SUNSHINE and SUNRISE trials, which assessed subcutaneous secukinumab 300 mg every 2 (SECQ2W) and 4 (SECQ4W) weeks in adults with moderate to severe HS, were analyzed. Assessments included changes from baseline in IHS4 and severity classification up to Week 52; IHS4‐55, IHS4‐75, IHS4‐90 responses (55%, 75% and 90% reduction in IHS4) and concordance between IHS4‐55 and HS clinical response (HiSCR), at Weeks 16 and 52.In total, 1084 patients (SECQ2W = 361; SECQ4W = 360; placebo = 363) were analyzed. At Week 16, SECQ2W and SECQ4W demonstrated a numerically higher reduction in IHS4 from baseline versus placebo (adjusted mean [95% CI]: −10.80 [−12.30 to −9.30] and −9.46 [−10.96 to −7.96] vs. −4.92 [−6.43 to −3.41]); the reduction was maintained until Week 52 in both dose regimens. A greater proportion of patients achieved IHS4‐55 with SECQ2W (43.4%) and SECQ4W (39.5%) versus placebo (31.5%) at Week 16, with further improvement at Week 52. Similar trends were observed for IHS4‐75 and IHS4‐90 responses. While no patients had mild disease based on IHS4 (80.7% had severe and 19.3% had moderate HS) at baseline, a greater proportion of patients were categorized as having mild disease at Week 16 in the SECQ2W (25.9%) and SECQ4W (24.0%) groups versus placebo (16.4%); this trend continued up to Week 52 in both dose regimens. Strong concordance (>85%) was observed between IHS4‐55 and HiSCR.Both SECQ2W and SECQ4W demonstrated efficacy in improving treatment response as measured by IHS4 and reducing disease severity versus placebo at Week 16 and these improvements were sustained through Week 52. These findings support that the dynamic and dichotomous IHS4 can efficiently detect treatment response changes in clinical trial settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Validation of a Dermatoscopy-Based Algorithm for the Diagnosis of Acral Melanoma.

Author

Müller, Christoph, Kittler, Harald, Tschandl, Philipp, Rinner, Christoph, Grausenburger, Marie-Luise, Kyrgidis, Athanassios, Koga, Hiroshi, Moscarella, Elvira, Apalla, Zoe, Di Stefani, Alessandro, Kobayashi, Ken, Lazaridou, Elisabeth, Longo, Caterina, Phan, Alice, Saida, Toshiaki, Sotiriou, Elena, Tanaka, Masaru, Thomas, Luc, Zalaudek, Iris, and Argenziano, Giuseppe

Subjects
NEVUS, MELANOMA diagnosis, SENSITIVITY & specificity (Statistics), DERMOSCOPY, MELANOMA
Abstract

Introduction: Diagnosis of acral melanocytic lesions can be challenging. The BRAAFF checklist was introduced as a tool to help differentiate between acral nevi and melanoma but has not been validated. Methods: We asked raters with varying expertise in dermatoscopy to diagnose dermatoscopic images of 533 acral nevi and 144 melanomas via an online platform with and without use of the BRAAFF checklist. From the ratings, we calculated sensitivity, specificity, and interrater agreement. Additionally, a new simplified version of the checklist was also tested. Results: We collected 6,880 ratings from 175 readers. The BRAAFF checklist achieved a sensitivity of 92.5% and a specificity of 65.0%, which was similar to diagnosis from pattern recognition (sensitivity 90.0%, specificity: 72.1%). Interrater agreement for the BRAAFF criteria ranged from fair to moderate, with lowest agreement for parallel ridge and fibrillar pattern (alpha = 0.31) and highest for asymmetry of colors and structures (alpha = 0.46). Agreement and diagnostic accuracy were higher for more experienced readers. A simplified version with only two criteria achieved similar sensitivity (95.0%) and lower specificity (60.0%) as the original BRAAFF checklist. Conclusion: The BRAAFF checklist is a useful tool for the diagnosis of melanocytic acral lesions with acceptable sensitivity and reasonable specificity but is not superior to pattern recognition. A simplified version of the checklist could be easier to use with equal sensitivity while exhibiting a modest reduction in specificity. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Dermoscopy in general dermatology (non-neoplastic dermatoses) of skin of colour: a comparative retrospective study by the International Dermoscopy Society

Author

Errichetti, Enzo, Ankad, Balachandra Suryakant, Sonthalia, Sidharth, Jha, Abhijeet Kumar, Keshavamurthy, Vinay, Kyrgidis, Athanassios, Neema, Shekhar, Chatterjee, Manas, Kaliyadan, Feroze, Dogra, Sunil, Khare, Soumil, Kelati, Awatef, Akay, Bengu Nisa, Cabo, Horacio, Bhat, Yasmeen Jabeen, Bosseila, Manal, Gupta, Atula, Nair, Pragya, Gaikwad, Sakshi, Jayasree, Puravoor, Sabban, Emilia Noemi Cohen, Stinco, Giuseppe, Apalla, Zoe, Zalaudek, Iris, and Lallas, Aimilios

Published
2020
Full Text
View/download PDF

23. Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients

Author

Dixon, Anthony J., primary, Kyrgidis, Athanassios, additional, Steinman, Howard K., additional, Dixon, John B., additional, Sladden, Michael, additional, Garbe, Claus, additional, Lallas, Aimilios, additional, Zachary, Christopher B., additional, Leiter‐Stöppke, Ulrike, additional, Smith, Harvey, additional, Nirenberg, Alexander, additional, Zouboulis, Christos C., additional, Longo, Caterina, additional, Argenziano, Giuseppe, additional, Apalla, Zoe, additional, Popescu, Catalin, additional, Tzellos, Thrasyvoulos, additional, Anderson, Stuart, additional, Nanz, Lena, additional, Cleaver, Lloyd, additional, and Thomas, J. Meirion, additional

Published
2024
Full Text
View/download PDF

33. BAUSSS biomarker further validated as a key risk staging tool for patients with primary melanoma.

Author

Dixon, Anthony J., Kyrgidis, Athanassios, Sladden, Michael, Nirenberg, Alexander, Steinman, Howard K., Smith, Harvey, Zachary, Christopher B., Anderson, Stuart, Leiter‐Stöppke, Ulrike, Longo, Caterina, and Apalla, Zoe

Subjects
*SENTINEL lymph node biopsy, *CONFIDENCE intervals, *MEDICAL care costs, *SURVIVAL rate, *OVERALL survival
Abstract

The article discusses the validation of the BAUSSS biomarker as a risk staging tool for patients with primary melanoma. The BAUSSS algorithm incorporates Breslow thickness, age, ulceration, subtype, sex, and site to assess prognosis. The authors compare the BAUSSS biomarker to other nomograms and conclude that Lifemath is the most reliable online tool for melanoma prognosis. They address concerns raised by another study and maintain that BAUSSS is a simple and effective predictor of survival risk in melanoma patients. The addition of sentinel lymph node biopsy status to BAUSSS improves accuracy but may not be meaningful in all cases. [Extracted from the article]

Published
2024
Full Text
View/download PDF

37. Melanoma in children: A systematic review and individual patient meta‐analysis

Author

Pampena, Riccardo, primary, Piccolo, Vincenzo, additional, Muscianese, Marta, additional, Kyrgidis, Athanassios, additional, Lai, Michela, additional, Russo, Teresa, additional, Briatico, Giulia, additional, Di Brizzi, Eugenia Veronica, additional, Cascone, Giovanni, additional, Pellerone, Sebastiano, additional, Longo, Caterina, additional, Moscarella, Elvira, additional, and Argenziano, Giuseppe, additional

Published
2023
Full Text
View/download PDF

39. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort

Author

Van Straalen, Kelsey R., Tzellos, Thrasyvoulos, Alavi, Afsaneh, Benhadou, Farida, Cuenca-Barrales, Carlos, Daxhelet, Mathilde, Daoud, Mathieu, Efthymiou, Ourania, Giamarellos-Bourboulis, Evangelos J., Guillem, Philippe, Gulliver, Wayne, Jemec, Gregor B.E., Katoulis, Alexander, Koenig, Anke, Lazaridou, Elizabeth, Lowes, Michelle A., Marzano, Angelo V., Matusiak, Lukasz, Molina-Leyva, Alejandro, Moltrasio, Chiara, Pinter, Andreas, Potenza, Concetta, Prens, Errol P., Romaní, Jorge, Saunte, Ditte M., Sayed, Christopher, Skroza, Nevena, Stergianou, Dimitra, Szepietowski, Jacek C., Trigoni, Anastasia, Vilarrasa, Eva, Kyrgidis, Athanassios, Zouboulis, Christos C., Van Der Zee, Hessel H., Van Straalen, Kelsey R., Tzellos, Thrasyvoulos, Alavi, Afsaneh, Benhadou, Farida, Cuenca-Barrales, Carlos, Daxhelet, Mathilde, Daoud, Mathieu, Efthymiou, Ourania, Giamarellos-Bourboulis, Evangelos J., Guillem, Philippe, Gulliver, Wayne, Jemec, Gregor B.E., Katoulis, Alexander, Koenig, Anke, Lazaridou, Elizabeth, Lowes, Michelle A., Marzano, Angelo V., Matusiak, Lukasz, Molina-Leyva, Alejandro, Moltrasio, Chiara, Pinter, Andreas, Potenza, Concetta, Prens, Errol P., Romaní, Jorge, Saunte, Ditte M., Sayed, Christopher, Skroza, Nevena, Stergianou, Dimitra, Szepietowski, Jacek C., Trigoni, Anastasia, Vilarrasa, Eva, Kyrgidis, Athanassios, Zouboulis, Christos C., and Van Der Zee, Hessel H.

Abstract

Background: Previously, a new dichotomous outcome was developed, calculated as 55% reduction in the International Hidradenitis Suppurativa 4 (IHS4-55) score. It was validated in datasets of adalimumab and placebo-treated HS patients. External validation is an important aspect of clinical outcomes. Objectives: We aimed to externally validate the novel dichotomous IHS4-55 in a non-biologic treated dataset of HS patients. Methods: Data from a previously published European-wide prospective clinical study of antibiotic treatment of HS patients were used to assess the association of IHS4-55 achievement with individual reduction in inflammatory nodules, abscesses, and draining tunnels. Moreover, the associations between IHS4-55 positivity and achievement of the minimal clinically important differences (MCIDs) for Dermatology Life Quality Index (DLQI), Numerical Rating Scale (NRS) Pain, and NRS Pruritus were analyzed. Results: Data were obtained from 283 individual patients, of which 36.4% (103/283) were treated with clindamycin and rifampicin and 63.6% (180/283) with tetracyclines for 12 weeks. Achievers of the IHS4-55 demonstrated a significant reduction the counts of inflammatory nodules, abscesses, and draining tunnels (all p < 0.001). Additionally, IHS4-55 achievers had an odds ratio for achieving the MCID of DLQI, NRS Pain, and NRS Pruritus of 2.16 (95% CI 1.28-3.65, p < 0.01), 1.79 (95% CI 1.10-2.91, p < 0.05), and 1.95 (95% CI 1.18-3.22, p < 0.01), respectively. Conclusions: This study shows the external validity of the novel IHS4-55 by demonstrating a significant association between IHS4-55 achievement and a reduction in inflammatory lesion counts as well as achievement of MCIDs for DLQI, NRS Pain, and NRS Pruritus in an antibiotic-treated cohort. These findings support the use of the IHS4-55 as a novel primary outcome measure in clinical trials.

Published
2023

40. Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa

Author

Tzellos, Thrasivoulos, van Straalen, Kelsey R., Kyrgidis, Athanassios, Alavi, Afsaneh, Goldfarb, Noah, Gulliver, Wayne, Jemec, Gregor B.E., Lowes, Michelle A., Marzano, Angelo Valerio, Prens, Errol P., Sayed, Christopher J., van der Zee, Hessel H., Zouboulis, Christos C., Tzellos, Thrasivoulos, van Straalen, Kelsey R., Kyrgidis, Athanassios, Alavi, Afsaneh, Goldfarb, Noah, Gulliver, Wayne, Jemec, Gregor B.E., Lowes, Michelle A., Marzano, Angelo Valerio, Prens, Errol P., Sayed, Christopher J., van der Zee, Hessel H., and Zouboulis, Christos C.

Abstract

Background: Validated, inclusive and easy-to-use outcomes for hidradenitis suppurativa are essential both in the clinical trial setting and clinical practice. The continuous IHS4 is a validated tool that dynamically assesses nodules/abscesses/draining tunnels and classifies disease severity as mild/moderate/severe. However, dichotomous outcomes are often required for clinical trials reporting. Objective: To develop and validate a dichotomous outcome based on IHS4 that can be used in clinical trial settings and day-to-day clinical practice. Methods: De-identified data from the PIONEER-I and -II studies were accessed through Vivli. Potential IHS4 thresholds were analysed using baseline to Week 12 data from adalimumab- and placebo-treated hidradenitis suppurativa patients in the PIONEER-I trial. The final threshold was chosen based on its ability to discriminate between patients treated with adalimumab or placebo and its association with reduction in inflammatory lesions. The final threshold was validated using data from baseline to Week 12 from adalimumab- and placebo-treated hidradenitis suppurativa patients in both the PIONEER-II and the combined PIONEER-I and -II studies. Results: The best performing cut-off for the IHS4 was a 55% reduction of the IHS4 score (IHS4-55). Patients who achieved the IHS4-55 had an odd's ratio of 2.00 [95%-CI 1.26–3.18, p = 0.003], 2.79 (95%-CI 1.76–4.43, p < 0.001) and 2.16 (95%-CI 1.43–3.29, p < 0.001) for being treated with adalimumab rather than placebo in PIONEER-I, PIONEER-II and the combined dataset, respectively. Additionally, the achievement of the IHS4-55 was associated with a significant reduction in inflammatory nodules, abscesses and draining tunnels in all analysed datasets. Conclusions: IHS4-55, a novel dichotomous IHS4 version, based on a 55% reduction of the total score was developed. The IHS4-55 performs similarly to the HiSCR in discriminating between adalimumab- and placebo-treated hidradenitis suppurativa pa

Published
2023

42. Clinical and dermoscopic features of atypical Spitz tumors: A multicenter, retrospective, case-control study

Author

Moscarella, Elvira, Lallas, Aimilios, Kyrgidis, Athanassios, Ferrara, Gerardo, Longo, Caterina, Scalvenzi, Massimiliano, Staibano, Stefania, Carrera, Cristina, Díaz, M.Alba, Broganelli, Paolo, Tomasini, Carlo, Cavicchini, Stefano, Gianotti, Raffaele, Puig, Susana, Malvehy, Josep, Zaballos, Pedro, Pellacani, Giovanni, and Argenziano, Giuseppe

Published
2015
Full Text
View/download PDF

45. External validation of the IHS4-55 in a European antibiotic-treated HS cohort

Author

van Straalen, Kelsey R., primary, Tzellos, Thrasyvoulos, additional, Alavi, Afsaneh, additional, Benhadou, Farida, additional, Cuenca-Barrales, Carlos, additional, Daxhelet, Mathilde, additional, Daoud, Mathieu, additional, Efthymiou, Ourania, additional, Giamarellos-Bourboulis, Evangelos J., additional, Guillem, Philippe, additional, Gulliver, Wayne, additional, Jemec, Gregor Borut Ernst, additional, Katoulis, Alexandros, additional, Koenig, Anke, additional, Lazaridou, Elizabeth, additional, Lowes, Michelle A., additional, Marzano, Angelo V., additional, Matusiak, Łukasz, additional, Molina-Leyva, Alejandro, additional, Moltrasio, Chiara, additional, Pinter, Andreas, additional, Potenza, Concetta, additional, Prens, Errol P., additional, Romaní, Jorge, additional, Saunte, Ditte Marie L., additional, Sayed, Christopher J, additional, Skroza, Nevena, additional, Stergianou, Dimitra, additional, Szepietowski, Jacek C., additional, Trigoni, Anastasia, additional, Vilarrasa, Eva, additional, Kyrgidis, Athanassios, additional, Zouboulis, Christos C., additional, and van der Zee, Hessel H., additional

Published
2023
Full Text
View/download PDF

48. The Natural Evolution of Nevi with Peripheral Globules

Author

Ilut, Paula Anca, primary, Camela, Elisa, additional, Lallas, Konstantinos, additional, Papageorgiou, Chryssoula, additional, Manoli, Sofia-Magdalini, additional, Kyrgidis, Athanassios, additional, Liopyris, Konstantinos, additional, Sgouros, Dimitrios, additional, Apalla, Zoe, additional, and Lallas, Aimilios, additional

Published
2023
Full Text
View/download PDF

50. Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable

Author

Dixon, Anthony, primary, Kyrgidis, Athanassios, additional, Zachary, Christopher, additional, Dixon, John, additional, Popescu, Catalin, additional, Sladden, Michael, additional, Apalla, Zoe, additional, Anderson, Stuart, additional, Argenziano, Giuseppe, additional, Ioannides, Demitrios, additional, Nirenberg, Alexander, additional, Lallas, Aimillios, additional, Zagarella, Samuel, additional, Longo, Caterina, additional, Smith, Harvey, additional, Steinman, Howard, additional, Tzellos, Thrasivoulos, additional, Cleaver, Lloyd, additional, Leahey, Ken, additional, Zouboulis, Christos C., additional, and Thomas, J. Meirion, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results